CLINICAL_TRIALS
trial_result
· 2014-09-25
Clinical Trial Update: Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC) [Phase 2]
Summary
A Phase 2 trial comparing two dosing schedules of sunitinib in metastatic renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Asan Medical Center | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED